Corbus CEO to Discuss Obesity Drug Pipeline at BMO Metabolic Health Summit
Event summary
- Corbus Pharmaceuticals CEO Yuval Cohen to participate in a panel discussion at the BMO 2026 Metabolic Health Summit on March 24, 2026.
- Corbus is developing CRB-913, an orally delivered CB1 inverse agonist for obesity, with Phase 1b trial completion expected in summer 2026.
- CRB-913 demonstrated rapid weight loss and favorable GI tolerability in a 14-day Phase 1a study.
- Corbus also has CRB-701 in development for Nectin-4-expressing tumors.
The big picture
Corbus Pharmaceuticals is focusing on its obesity drug pipeline at a time when the metabolic health sector is seeing increased investment and innovation. The company's participation in the BMO summit highlights the strategic importance of CRB-913, which could offer a novel treatment option for chronic obesity if clinical success continues. The obesity drug market is highly competitive, with several new therapies in development, making Corbus' ability to differentiate CRB-913 a key factor in its long-term prospects.
What we're watching
- Clinical Progress
- Whether CRB-913 can maintain its favorable safety and efficacy profile in larger, longer-term studies.
- Market Positioning
- How Corbus positions CRB-913 against competitors in the crowded obesity drug market.
- Regulatory Pathway
- The pace at which Corbus advances CRB-913 through Phase 2 and potential pivotal trials.
Related topics